India’s pharmaceutical sector recorded its strongest monthly performance in over two years in June, with the domestic market expanding 16% year-on-year.
The surge coincides with the commencement of a proposed two-year transition period ahead of steep United States tariffs on imported generic medicines, according to a report by Equirus Research.
The US administration has outlined a phased tariff structure on generic drug imports, starting at zero percent and escalating to 200% by 2028.
First-quarter FY27 growth also accelerated to 13.5%, signaling broad-based momentum within the Indian domestic market.
This internal strength offers a critical counterweight for manufacturers as they navigate the early stages of a trade policy shift that threatens their largest export destination.
The US administration has outlined a phased tariff structure on generic drug imports, starting at zero percent and escalating to 200% by 2028.
The policy aims to compel pharmaceutical producers to relocate manufacturing capacity to the United States.